Amylin vs GLP-1 comes down to origin and insulin. GLP-1 comes from the gut and boosts insulin after meals, while amylin comes from the pancreas and slows eating without raising insulin. TelosRX compares both side by side below.
Two hormones. Both tell your brain you've had enough.
Both are now the backbone of the newest weight-management research. So why do they get lumped together, and what actually separates them?
The short answer: they overlap in effect but differ in origin, receptors, blood sugar action, and how far along the drugs are. This guide puts them side by side. You'll get a comparison table, the key trials, and a plain look at what's realistic today.
Amylin vs GLP-1 at a Glance
Here's the head-to-head. Skim this first, then read the sections that matter to you.
| Feature | Amylin | GLP-1 |
|---|---|---|
| Where it's made | Pancreatic beta cells (the insulin-making cells) | L-cells in the lower small intestine and colon |
| Released with | Insulin, after you eat | Other gut hormones, after food reaches the gut |
| Main receptors | Calcitonin receptor paired with RAMP proteins (receptor helpers) | GLP-1 receptor |
| Effect on insulin | Does not raise insulin | Raises insulin when glucose is high |
| Effect on glucagon | Lowers after-meal glucagon | Lowers glucagon when glucose is high |
| Stomach emptying | Slows it | Slows it |
| Key brain target | Area postrema in the hindbrain | Hindbrain and hypothalamus |
| Approved drug examples | Pramlintide (Symlin), for diabetes only | Semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro) |
| Investigational examples | Cagrilintide, and amylin-GLP-1 combinations | Oral and next-generation multi-agonists |
| Typical dosing of current drugs | Pramlintide: before major meals; cagrilintide: studied once weekly | Semaglutide and tirzepatide: once weekly |
| Evidence for weight management | Growing, mostly from recent trials | Large, long-term phase 3 trials |
The pattern is clear. Both slow digestion and signal fullness.
Only GLP-1 pushes insulin. And only GLP-1 has approved weight-management drugs today.
What Is Amylin?
Amylin is a 37-amino-acid hormone made by the same pancreatic cells that make insulin. It's released alongside insulin whenever you eat. Think of it as insulin's quieter partner.
Its job is to smooth out the after-meal period. It slows how fast food leaves your stomach.
It trims the glucagon spike that would otherwise push more sugar into your blood. And it tells your brain to stop eating.
People with type 1 diabetes make little or no amylin. Many people with advanced type 2 diabetes make less of it too. That gap is why the first amylin drug was built for diabetes, not weight.
Why amylin was hard to turn into a drug
Human amylin clumps. It forms sticky fibrils (tangled protein strands) that make it a poor drug on its own. Chemists had to rebuild it to keep it stable in a vial.
Pramlintide was the first fix. It swaps three amino acids to reduce clumping. But it clears fast.
Researchers describe it as needing up to three daily injections because of its short half-life. Cagrilintide came next. It adds a fatty-acid tail that lets it ride on blood proteins and last far longer.
What Is GLP-1?
GLP-1 (glucagon-like peptide-1) is a gut hormone released when food reaches your intestine. It's part of the incretin family, hormones that amplify insulin after meals.
Natural GLP-1 lasts only minutes in the blood. An enzyme called DPP-4 chops it up fast.
Drug makers solved that with modified versions that resist the enzyme and bind to blood proteins. That's how semaglutide and tirzepatide reach once-weekly dosing.
GLP-1 drugs act in several places at once:
- Pancreas: more insulin, less glucagon, but only when glucose is elevated
- Stomach: slower emptying, so meals feel bigger
- Brain: reduced hunger and fewer food cravings
For a deeper look at the brain side, see our breakdown of how GLP-1 suppresses appetite.
How Each Hormone Quiets Hunger
Here's where the two really differ. They both end in "I'm full," but they take different roads.
A detailed review of amylin and GLP-1 in the control of eating describes both as satiation signals. That means they help end a meal, rather than delay the next one.
Amylin's route
Amylin acts directly on the area postrema. That's a small hindbrain region with a leaky blood-brain barrier.
Hormones in the blood can reach it easily. From there, signals travel to other appetite centers.
GLP-1's route
GLP-1 signals partly through the vagus nerve, the gut-to-brain cable. Long-acting GLP-1 drugs also reach hindbrain and hypothalamic areas that govern hunger and food reward.
Why that matters
Because the pathways differ, the effects can stack. Animal research in the review above suggests amylin and GLP-1 signals can add to each other. That idea is the entire logic behind combination drugs.
Blood Sugar Effects: Amylin vs GLP-1
Both hormones help after-meal glucose. They just do it differently.
- GLP-1 raises insulin in a glucose-dependent way. High sugar, more insulin. Normal sugar, little extra.
- Amylin leaves insulin alone. It works by slowing food delivery and trimming glucagon.
This is a big reason GLP-1 drugs can stand alone in type 2 diabetes. Pramlintide, by contrast, is approved only as an add-on to mealtime insulin.
If you're curious how GLP-1s interact with insulin resistance specifically, our guide on GLP-1 and insulin resistance goes deeper.
The Drugs Compared: Pramlintide, Cagrilintide, Semaglutide, Tirzepatide
Hormones are one thing. The drugs built on them are another. Here's where each stands.
| Drug | Class | FDA status | Dosing studied or labeled | Main use |
|---|---|---|---|---|
| Pramlintide (Symlin) | Amylin analog | Approved (2005) | Injection before major meals | Add-on to mealtime insulin in diabetes |
| Cagrilintide | Long-acting amylin analog | Investigational, not FDA-approved | Once weekly in trials | Studied for weight management |
| Semaglutide (Wegovy, Ozempic) | GLP-1 receptor agonist | Approved | Once weekly injection; oral form also exists | Chronic weight management; type 2 diabetes |
| Tirzepatide (Zepbound, Mounjaro) | GIP and GLP-1 dual agonist | Approved | Once weekly injection | Chronic weight management; type 2 diabetes |
| Cagrilintide + semaglutide | Amylin + GLP-1 combination | Investigational, not FDA-approved | Once weekly in trials | Studied for weight management |
Note the gap. No amylin-based drug is approved for weight management in the U.S. as of this writing. Every approved weight-management option in this table works through GLP-1.
What the Head-to-Head Evidence Shows
The biggest test of amylin plus GLP-1 so far is REDEFINE 1. It was a 68-week, phase 3 trial in 3,417 adults without diabetes who had obesity or overweight with a related condition.
Participants got one of four options, plus lifestyle support:
- Cagrilintide 2.4 mg plus semaglutide 2.4 mg
- Semaglutide 2.4 mg alone
- Cagrilintide 2.4 mg alone
- Placebo
According to the published REDEFINE 1 results, the estimated mean body-weight change at week 68 was −20.4% with the combination versus −3.0% with placebo. Gastrointestinal side effects were common, reported in 79.6% of the combination group versus 39.9% on placebo. Most were mild to moderate and faded over time.
What this does and doesn't tell you: it's an average across thousands of people in a controlled setting. It isn't a prediction for any individual. Results vary widely, and the combination isn't approved.
We walk through the full trial design in our REDEFINE trial guide.
Side Effects: Amylin vs GLP-1
Both classes share a theme: the gut complains first. That makes sense. Both slow digestion.
| Consideration | Amylin-based drugs | GLP-1-based drugs |
|---|---|---|
| Nausea | Common, especially early | Common, especially during dose increases |
| Vomiting, constipation, diarrhea | Reported | Reported |
| Low blood sugar | Pramlintide carries a boxed warning for severe lows when used with insulin | Low risk alone; higher with insulin or sulfonylureas |
| Boxed warnings | Pramlintide: severe hypoglycemia with insulin | Semaglutide and tirzepatide: thyroid C-cell tumor warning |
| Other label warnings | Not suited to people with gastroparesis | Pancreatitis, gallbladder issues, kidney strain from dehydration |
This table is a starting point, not a full safety review. Your prescriber and the product labeling are the final word. Anyone with a history of pancreatitis, medullary thyroid cancer, or severe stomach motility problems should raise it before starting any of these.
Why Researchers Combine Amylin and GLP-1
If GLP-1 works well, why add amylin? Three reasons come up again and again in the research.
- Different pathways. Amylin and GLP-1 reach appetite centers by different routes, so their effects can add up.
- Different feel. Some researchers suggest amylin produces fullness with less of the "food aversion" some people report on GLP-1s. That idea is still being studied.
- Lean mass questions. Early work is exploring whether amylin-based approaches affect body composition differently. The data are not settled.
Two approaches are in development. One is co-administration, two separate molecules given together, as in CagriSema.
The other is a single molecule that hits both receptors, sometimes called a unimolecular co-agonist. Both remain investigational and are not FDA-approved.
Amylin vs GLP-1: Which to Consider?
Here's the honest version. For weight management today, the realistic choice isn't really "amylin or GLP-1." It's which GLP-1-based option fits you, if any.
If you're exploring weight management now
GLP-1-based medicines are the established route. They have years of phase 3 data and FDA-approved brands.
Compounded versions also exist. Compounded semaglutide and tirzepatide are not FDA-approved, and any prescription is subject to medical approval by a licensed provider.
Ready to see what fits? Review the GLP-1 options at TelosRX.
You'll complete an asynchronous intake online, and a licensed provider reviews it on their schedule, not yours. No video call needed.
If you're interested in amylin
Cagrilintide is investigational. It isn't FDA-approved for any use, and it isn't something TelosRX offers.
Pramlintide is approved, but only for people with diabetes who use mealtime insulin. If amylin research interests you, a clinical trial may be the legitimate path.
If you have diabetes
Your situation is different. Both classes interact with blood sugar medicines, especially insulin. Decisions here belong with a clinician who knows your full regimen.
Questions worth asking your provider
- Is a GLP-1-based medicine appropriate for my history?
- How would it interact with my current medications?
- What side effects should prompt me to pause and check in?
- How will we pace dose changes to keep nausea manageable?
- What should I eat, and how much protein should I aim for?
For a closer look at how the leading amylin candidate compares with the leading GLP-1, read our cagrilintide vs semaglutide comparison.
Eating Well on Either Pathway
Here's the unglamorous part. Hormone-based medicines shrink appetite, but they don't choose your food. What you eat on a smaller appetite matters more, not less.
A few habits come up again and again in clinical programs:
- Protein first. Smaller meals make it easy to under-eat protein. Start each plate with it.
- Fiber and fluids. Slower digestion can mean constipation. Vegetables, legumes, and water help.
- Smaller, slower meals. Both hormones slow stomach emptying. Big, rich meals are the usual nausea trigger.
- Strength training. Resistance work helps you hold on to muscle while your weight changes.
- Limit alcohol. It adds calories and can worsen nausea and low blood sugar risk.
None of this is glamorous. It's also the part every successful trial program included.
The medicine changes the appetite signal. The habits decide what you do with it.
Common Myths About Amylin and GLP-1
A few ideas travel fast online. Here's how they hold up.
- "Amylin drugs are just weaker GLP-1s." Not quite. They act on different receptors and don't raise insulin. They're a different tool, not a smaller copy.
- "You can get CagriSema now." No. The combination is investigational and not FDA-approved. Anything sold as "CagriSema" outside a trial deserves real skepticism.
- "GLP-1s only work by making you nauseous." Nausea is a side effect, not the mechanism. The appetite effects run through brain and gut signaling.
- "Hormone drugs replace diet and exercise." Every major trial paired medication with lifestyle support. Food quality, protein, and strength training still matter.
Frequently Asked Questions
What is the main difference between amylin and GLP-1?
Amylin comes from the pancreas and is released with insulin. GLP-1 comes from the gut. Both slow stomach emptying and signal fullness. The key difference is insulin: GLP-1 raises insulin when blood sugar is high, while amylin does not. They also act on different receptors and partly different brain regions, which is why researchers study them together.
Is cagrilintide a GLP-1?
No. Cagrilintide is a long-acting amylin analog. It acts on amylin and calcitonin receptors, not the GLP-1 receptor. It is often studied alongside semaglutide, a GLP-1 drug, which is why the two get confused. Cagrilintide is investigational and not FDA-approved for any use, alone or in combination.
Is there an FDA-approved amylin drug?
Yes, one. Pramlintide, sold as Symlin, was approved in 2005 for people with type 1 or type 2 diabetes who use mealtime insulin. It is an add-on, not a standalone option, and it is not approved for weight management. It carries a boxed warning about severe low blood sugar when used with insulin.
Can you take amylin and GLP-1 together?
In clinical trials, yes. The REDEFINE program tested cagrilintide with semaglutide as a weekly combination. Outside of trials, no approved amylin-plus-GLP-1 product exists for weight management. Combining medicines on your own is not advised. Any combination should be evaluated and prescribed by a licensed provider who knows your history.
Do amylin drugs cause less nausea than GLP-1s?
The evidence doesn't show that clearly. Both classes commonly cause nausea, especially early on. In REDEFINE 1, gastrointestinal side effects were reported in most people on the amylin-GLP-1 combination, though they were mostly mild to moderate and temporary. Slow dose increases are the usual strategy for tolerability with either class.
How can I start a GLP-1 medication online?
With TelosRX, you complete an asynchronous online intake about your health history and goals. A licensed provider reviews it without a live call. If appropriate, a prescription may be issued, subject to medical approval by a licensed provider. Approval is not guaranteed, and compounded GLP-1 medications are not FDA-approved.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.